Psychedelic-Assisted Therapy
A comprehensive guide to psychedelic-assisted therapy: how psilocybin, MDMA, and ketamine are used in clinical settings to treat depression, PTSD, and more.
What Is Psychedelic-Assisted Therapy?
Psychedelic-assisted therapy is a treatment approach that combines the administration of a psychedelic or psychoactive substance with structured psychotherapy, in a carefully controlled clinical setting. Unlike recreational use, the psychedelic experience is embedded within a therapeutic framework that includes preparation sessions before, guided support during, and integration sessions after the drug experience.
The three substances with the most developed clinical evidence are:
- Psilocybin: The active compound in certain mushrooms, studied primarily for treatment-resistant depression and end-of-life anxiety.
- MDMA: Studied primarily as an adjunct to psychotherapy for PTSD. MDMA-assisted therapy has received FDA breakthrough therapy designation.
- Ketamine: An anesthetic with rapid antidepressant effects, currently the only psychedelic-related treatment available through legal prescription (as esketamine/Spravato, FDA-approved for treatment-resistant depression).
How It Works
Psychedelic-assisted therapy is fundamentally different from simply taking a psychedelic substance. The therapy model typically follows three phases:
1. Preparation (1-3 sessions)
Before the psychedelic session, you work with a therapist to:
- Establish trust and therapeutic rapport
- Discuss your history, goals, and intentions for the experience
- Learn what to expect during the session
- Develop strategies for navigating difficult moments during the experience
2. Dosing Session (1 day)
The psychedelic session takes place in a comfortable, carefully designed environment. Two therapists are typically present throughout. The experience lasts several hours, depending on the substance:
- Psilocybin: 4 to 6 hours. Participants often lie down with an eye mask, listening to a curated music playlist. The therapists provide supportive presence without directing the experience.
- MDMA: 6 to 8 hours. MDMA sessions tend to be more interactive, with the therapist engaging in conversation as the participant explores traumatic memories with reduced fear and increased empathy.
- Ketamine: 40 minutes to 2 hours, depending on the route of administration. Ketamine produces dissociative effects and can be administered via IV infusion, intramuscular injection, or nasal spray (esketamine).
3. Integration (2-4 sessions)
Integration sessions — often considered the most important phase — help you make sense of the psychedelic experience and translate insights into lasting change. This involves:
- Processing emotions, images, and insights from the session
- Connecting the experience to your therapeutic goals
- Developing concrete plans for behavioral and lifestyle changes
- Working through any challenging material that emerged
67%
What to Expect
The overall treatment process spans several weeks to months:
- Medical screening: Thorough medical and psychiatric evaluation to ensure safety. Certain conditions (psychotic disorders, uncontrolled cardiovascular disease, certain medications) are contraindications.
- Preparation: Building the therapeutic relationship and preparing for the experience.
- Dosing day: A full day commitment in a clinical setting, with continuous medical monitoring.
- Recovery: You will need someone to drive you home. Most people take the following day off as well.
- Integration: Multiple sessions over the following weeks to process and apply what emerged.
For ketamine specifically, treatment protocols vary:
- IV ketamine infusions: Typically six infusions over two to three weeks.
- Esketamine (Spravato): FDA-approved nasal spray administered in a certified healthcare setting, with a two-hour monitoring period after each dose.
Conditions It Treats
Current evidence supports psychedelic-assisted therapy for:
- Treatment-resistant depression — psilocybin and ketamine have the strongest evidence
- PTSD — MDMA-assisted therapy has shown remarkable results in clinical trials
- End-of-life anxiety and depression — psilocybin has demonstrated rapid and sustained relief in people with terminal illness
- Alcohol and tobacco addiction — early-stage research with psilocybin shows promising results
- Obsessive-compulsive disorder — preliminary studies with psilocybin suggest potential benefit
Effectiveness
The evidence, while still growing, has been striking:
- Psilocybin for depression: A randomized controlled trial published in the New England Journal of Medicine found psilocybin therapy produced rapid and sustained reductions in depressive symptoms, with 67% of participants showing significant response.
- MDMA for PTSD: Phase 3 clinical trials showed 67% of participants no longer met criteria for PTSD after three MDMA-assisted therapy sessions, compared to 32% in the placebo group. Long-term follow-up showed effects were maintained.
- Ketamine/esketamine for depression: Esketamine is FDA-approved for treatment-resistant depression and acute suicidal ideation, with clinical trials demonstrating rapid onset of antidepressant effects — often within hours to days.
- Durability: A notable feature of psilocybin and MDMA therapy is that benefits often persist for months to years after just one to three dosing sessions, a pattern rarely seen with conventional treatments.
| Feature | Psychedelic-Assisted Therapy | EMDR | Brain Stimulation (TMS/ECT) |
|---|---|---|---|
| Primary mechanism | Altered states enabling deep processing | Bilateral stimulation during trauma recall | Direct modulation of brain activity |
| Number of sessions | 1-3 dosing sessions + prep/integration | 8-12 sessions | 20-30 (TMS) or 6-12 (ECT) |
| Onset of effect | Often rapid (days to weeks) | Gradual over treatment course | 2-4 weeks (TMS), 1-2 weeks (ECT) |
| Legal availability | Ketamine only (US); others in trials | Widely available | Widely available |
| Best for | Treatment-resistant depression, PTSD | PTSD, trauma | Treatment-resistant depression, OCD |
Related Articles
Psychedelic-Assisted Therapy
- Ketamine Therapy for Depression: What You Need to Know — The only legally available psychedelic-related treatment for depression.
- Psilocybin Therapy: Where the Research Stands — An up-to-date overview of clinical trial results and evolving legal access.
Crisis & Severe Depression
- Treatment for Suicidal Thoughts: Options That Can Help — How psychedelic-assisted therapy fits into treatment for acute suicidality, alongside other evidence-based options.
Frequently Asked Questions
Ketamine-based treatments, including the FDA-approved esketamine nasal spray (Spravato), are legal and available through licensed providers in the United States. Psilocybin has been decriminalized or approved for therapeutic use in some jurisdictions (Oregon, Colorado, and several cities), with state-regulated frameworks emerging. MDMA-assisted therapy is currently in the regulatory review process. The legal landscape is evolving rapidly.
In controlled clinical settings with proper screening, preparation, and supervision, psychedelic-assisted therapy has demonstrated a favorable safety profile in clinical trials. Serious adverse events have been rare. However, psychedelics are not appropriate for everyone — people with personal or family histories of psychotic disorders, certain cardiac conditions, or those taking specific medications may face elevated risks. Thorough medical screening is essential.
Challenging experiences can occur during psychedelic sessions, including intense emotions, difficult memories, or anxiety. In a therapeutic context, these experiences are not considered 'bad trips' but rather opportunities for therapeutic processing. Trained therapists are present throughout to provide support, and preparation sessions teach you how to navigate difficult moments. Research suggests that challenging experiences often lead to the most meaningful therapeutic outcomes when properly supported.
Clinical psychedelic-assisted therapy differs from recreational use in every way: medical screening ensures safety, pharmaceutical-grade substances ensure purity and precise dosing, the setting is carefully designed, trained therapists provide continuous support, and integration sessions help translate the experience into lasting change. The therapeutic framework is what makes this a treatment rather than simply a drug experience.
This depends on your current medications and treatment plan. Some medications, particularly SSRIs, may reduce the effects of psilocybin and MDMA. Ketamine has its own set of medication interactions. A thorough medication review with a qualified provider is essential before beginning psychedelic-assisted therapy. Never adjust medications on your own.
Learn About Psychedelic-Assisted Therapy Options
Connect with a qualified provider to learn whether ketamine treatment or clinical trial participation may be appropriate for your situation.
Take the Therapy QuizFurther Reading
- Ketamine Therapy for Depression: What You Need to Know — A comprehensive guide to the only legally available psychedelic-related treatment for depression.
- Psilocybin Therapy: Where the Research Stands — An up-to-date overview of clinical trial results and evolving legal access.
- Treatment for Suicidal Thoughts: Options That Can Help — How psychedelic-assisted therapy fits into treatment for acute suicidality.